Literature DB >> 21123948

Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling.

Ying Qu1, Jinhua Wang, Partha S Ray, Hua Guo, Jian Huang, Miyung Shin-Sim, Bolanle A Bukoye, Bingya Liu, Adrian V Lee, Xin Lin, Peng Huang, John W Martens, Armando E Giuliano, Ning Zhang, Ning-Hui Cheng, Xiaojiang Cui.   

Abstract

Cancer cells have an efficient antioxidant system to counteract their increased generation of ROS. However, whether this ability to survive high levels of ROS has an important role in the growth and metastasis of tumors is not well understood. Here, we demonstrate that the redox protein thioredoxin-like 2 (TXNL2) regulates the growth and metastasis of human breast cancer cells through a redox signaling mechanism. TXNL2 was found to be overexpressed in human cancers, including breast cancers. Knockdown of TXNL2 in human breast cancer cell lines increased ROS levels and reduced NF-κB activity, resulting in inhibition of in vitro proliferation, survival, and invasion. In addition, TXNL2 knockdown inhibited tumorigenesis and metastasis of these cells upon transplantation into immunodeficient mice. Furthermore, analysis of primary breast cancer samples demonstrated that enhanced TXNL2 expression correlated with metastasis to the lung and brain and with decreased overall patient survival. Our studies provided insight into redox-based mechanisms underlying tumor growth and metastasis and suggest that TXNL2 could be a target for treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123948      PMCID: PMC3007146          DOI: 10.1172/JCI43144

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  96 in total

Review 1.  Properties and biological activities of thioredoxins.

Authors:  G Powis; W R Montfort
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

Review 2.  Ras-related GTPases and the cytoskeleton.

Authors:  A Hall
Journal:  Mol Biol Cell       Date:  1992-05       Impact factor: 4.138

Review 3.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

Authors:  Jun-Li Luo; Hideaki Kamata; Michael Karin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.

Authors:  Sarah J Welsh; William T Bellamy; Margaret M Briehl; Garth Powis
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

6.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.

Authors:  Xiaobo Wang; Karine Belguise; Nathalie Kersual; Kathrin H Kirsch; Nora D Mineva; Florence Galtier; Dany Chalbos; Gail E Sonenshein
Journal:  Nat Cell Biol       Date:  2007-03-18       Impact factor: 28.824

Review 7.  Thioredoxin signaling as a target for cancer therapy.

Authors:  Garth Powis; D Lynn Kirkpatrick
Journal:  Curr Opin Pharmacol       Date:  2007-07-03       Impact factor: 5.547

8.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.

Authors:  Dohun Pyeon; Michael A Newton; Paul F Lambert; Johan A den Boon; Srikumar Sengupta; Carmen J Marsit; Craig D Woodworth; Joseph P Connor; Thomas H Haugen; Elaine M Smith; Karl T Kelsey; Lubomir P Turek; Paul Ahlquist
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

9.  Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species mediated damage.

Authors:  Se-Yeong Oh; Young-Woo Sohn; Jong-Whi Park; Hyo-Jung Park; Hye-Min Jeon; Tae-Kyung Kim; Joong-Seob Lee; Ji-Eun Jung; Xun Jin; Yong Gu Chung; Young-Ki Choi; Seungkwon You; Jang-Bo Lee; Hyunggee Kim
Journal:  Mol Cancer Ther       Date:  2007-08       Impact factor: 6.261

10.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Authors:  Yudi Pawitan; Judith Bjöhle; Lukas Amler; Anna-Lena Borg; Suzanne Egyhazi; Per Hall; Xia Han; Lars Holmberg; Fei Huang; Sigrid Klaar; Edison T Liu; Lance Miller; Hans Nordgren; Alexander Ploner; Kerstin Sandelin; Peter M Shaw; Johanna Smeds; Lambert Skoog; Sara Wedrén; Jonas Bergh
Journal:  Breast Cancer Res       Date:  2005-10-03       Impact factor: 6.466

View more
  58 in total

1.  Human glutaredoxin 3 forms [2Fe-2S]-bridged complexes with human BolA2.

Authors:  Haoran Li; Daphne T Mapolelo; Sajini Randeniya; Michael K Johnson; Caryn E Outten
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

Review 2.  Redox biology of the intestine.

Authors:  Magdalena L Circu; Tak Yee Aw
Journal:  Free Radic Res       Date:  2011-09-05

Review 3.  ROS in Cancer: The Burning Question.

Authors:  Iok In Christine Chio; David A Tuveson
Journal:  Trends Mol Med       Date:  2017-04-17       Impact factor: 11.951

4.  Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis.

Authors:  Hongyan Qi; Meng Lou; Yuexia Chen; Xiyong Liu; Naiming Chen; Jianzhen Shan; Zhiqiang Ling; Jing Shen; Lijun Zhu; Yun Yen; Shu Zheng; Jimin Shao
Journal:  Tumour Biol       Date:  2015-02-01

5.  Nuclear glutaredoxin 3 is critical for protection against oxidative stress-induced cell death.

Authors:  Khanh Pham; Rituraj Pal; Ying Qu; Xi Liu; Han Yu; Stephen L Shiao; Xinquan Wang; E O'Brian Smith; Xiaojiang Cui; George G Rodney; Ninghui Cheng
Journal:  Free Radic Biol Med       Date:  2015-05-11       Impact factor: 7.376

6.  A mammalian monothiol glutaredoxin, Grx3, is critical for cell cycle progression during embryogenesis.

Authors:  Lawrence Chan; Kendal D Hirschi; Ning-Hui Cheng; Wei Zhang; Wei-Qin Chen; Jianping Jin; Xiaojiang Cui; Nancy F Butte
Journal:  FEBS J       Date:  2011-06-02       Impact factor: 5.542

7.  Loss of glutaredoxin 3 impedes mammary lobuloalveolar development during pregnancy and lactation.

Authors:  Khanh Pham; Jie Dong; Xiqian Jiang; Ying Qu; Han Yu; Yisheng Yang; Walter Olea; Juan C Marini; Lawrence Chan; Jin Wang; Xander H T Wehrens; Xiaojiang Cui; Yi Li; Darryl L Hadsell; Ninghui Cheng
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-11-15       Impact factor: 4.310

Review 8.  Mitochondrial dynamics and metastasis.

Authors:  Dario C Altieri
Journal:  Cell Mol Life Sci       Date:  2018-11-10       Impact factor: 9.261

9.  Thioredoxin-like protein 2 is overexpressed in colon cancer and promotes cancer cell metastasis by interaction with ran.

Authors:  Yuanyuan Lu; Xiaodi Zhao; Kai Li; Guanhong Luo; Yongzhan Nie; Yongquan Shi; Yi Zhou; Gui Ren; Bin Feng; Zhenxiong Liu; Yan Pan; Ting Li; Xuegang Guo; Kaichun Wu; Antonio Miranda-Vizuete; Xin Wang; Daiming Fan
Journal:  Antioxid Redox Signal       Date:  2013-03-04       Impact factor: 8.401

10.  Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype.

Authors:  Haiquan Lu; Debangshu Samanta; Lisha Xiang; Huimin Zhang; Hongxia Hu; Ivan Chen; John W Bullen; Gregg L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.